Smoking Cessation
Conditions
Brief summary
The modest goal of this study is to replicate the behavioral outcomes of the opt out MUSC-Tobacco Treatment Program in the following three patient groups: 1) psychiatric inpatients housed in the Institute of Psychiatry (IOP) in Charleston; 2) non-IOP patients seen in Charleston; and 3) patients seen in the other four MUSC affiliated hospitals combined (i.e., Chester, Florence, Lancaster, and Marion). The aims and the design/methods utilized for evaluation will be the same for each of the three patient groups.
Interventions
BEHAVIORALEnhanced Care
Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
BEHAVIORALBasic Care
Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
Sponsors
Medical University of South Carolina
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18+ years and older * hospitalized cigarette smokers eligible for either enhanced or basic care * discharged from the hospital back to their home
Exclusion criteria
* patients without a phone number * those unable to communicate in the English language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported smoking prevalence 6-weeks after hospitalization. | Assessed 6-weeks post-discharge | Hypothesize that patients exposed to the enhanced care intervention compared to basic care will report a 2-fold higher 7-day non-smoker prevalence rate after hospitalization (i.e., 20% vs 10%) |
| Self-reported use of FDA Approved Smoking Cessation Medication | Assessed 6-weeks post-discharge | Hypothesize that patients exposed to the enhanced care intervention compared to basic care will report a 2.5-fold greater use of an FDA approved stop smoking medication after hospitalization (i.e., 20% vs 8%) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKenneth M Cummings, PhD
Medical University of South Carolina
Outcome results
None listed